TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On February 2, JPMorgan analyst Brian Cheng reduced the price target on TG Therapeutics (NASDAQ:TGTX) to $46 from $49 while maintaining the Overweight rating on the shares. The investment bank had recently updated the model on the company. TG Therapeutics presented its trial results on February 6 at a medical forum in San Diego, California. The presentation focused on the results of its Briumvi treatment for ...

Core Insights - TG Therapeutics (TGTX) shares increased nearly 7% in after-hours trading after the release of preliminary fourth-quarter and full-year 2025 results that exceeded expectations [1] - The company provided optimistic guidance for 2026, highlighting key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates [1] Financial Performance - TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, surpassing the previous guidance of $600 million and the Zacks Consensus Estimate of $604 million [3] - Briumvi U.S. net product revenues are projected to be around $182 million for the fourth quarter of 2025 [3] - For full-year 2025, Briumvi net product sales are expected to be approximately $594 million in the United States, exceeding the November guidance of around $585 million [4] 2026 Outlook & Pipeline Goals - TGTX anticipates 2026 revenues in the range of $875 million to $900 million, including $825 million to $850 million from U.S. Briumvi sales, indicating potential double-digit year-over-year growth compared to expected 2025 figures [7][8] - The company expects operating expenses of around $350 million for the full year 2026 [8] - Key milestones for 2026 include the announcement of pivotal topline data from the ENHANCE study, which aims to consolidate Briumvi infusions, and results from the subcutaneous Briumvi formulation [9][10] - TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with preliminary phase I data expected in the second half of 2026 [11]

Core Viewpoint - U.S. stock futures are trading lower, with several companies expected to report quarterly earnings, drawing investor attention [1] Company Earnings Expectations - Bank of America Corp (NYSE:BAC) is anticipated to report quarterly earnings of 96 cents per share on revenue of $27.87 billion, with shares slipping 0.1% to $54.51 in after-hours trading [1] - Citigroup Inc (NYSE:C) is expected to post quarterly earnings of $1.68 per share on revenue of $20.53 billion, with shares falling 0.1% to $116.15 in after-hours trading [1] - Wells Fargo & Co (NYSE:WFC) is projected to report quarterly earnings of $1.67 per share on revenue of $21.65 billion, with shares decreasing 0.2% to $93.38 in after-hours trading [1] Company Updates - TG Therapeutics, Inc. (NASDAQ:TGTX) provided preliminary fourth quarter revenue estimates, expecting U.S. net product revenue of approximately $182 million for Q4 and $594 million for the full year of 2025, with total global revenue for 2025 expected to be around $616 million [1] - Gelteq Ltd. (NASDAQ:GELS) reported positive preclinical results for its cannabinoid oral gel delivery platform, leading to a significant share price increase of 69.3% to $1.41 in after-hours trading [1]

TG Therapeutics Conference Call Summary Company Overview - **Company**: TG Therapeutics (NasdaqCM:TGTX) - **Focus**: B-cell mediated diseases, primarily multiple sclerosis (MS) - **Approved Drug**: Briumvi, an anti-CD20 monoclonal antibody for MS, launched in January 2023 - **Market Presence**: Available in 16 countries, with over 20,000 patients prescribed Briumvi to date [2][3] Core Market Insights - **Anti-CD20 Market**: Represents approximately $10 billion in sales, with Briumvi capturing about 20% of the total market share and one-third of the healthcare provider-administered segment [4][6] - **Growth Potential**: The anti-CD20 class holds a 50% market share in new prescriptions, indicating room for growth [4][5] Financial Performance - **2026 Revenue**: Total global revenues of $616 million, with U.S. net revenue of $594 million, reflecting a 90% year-over-year growth [7][9] - **Cumulative Revenue**: Exceeded $1 billion in cumulative net sales within less than three years of launch [6][7] - **Forecast for 2026**: Targeting $875 million to $900 million in global net revenue, primarily from U.S. sales [27][28] Product Development and Future Plans - **Upcoming Trials**: - Enhanced IV protocol aimed at consolidating dosing to simplify onboarding, with top-line data expected mid-2026 [18][19] - Development of a self-administered subcutaneous (subcu) version of Briumvi, with a pivotal study currently over 50% enrolled and a target launch in 2028 [20][21] - **Expansion Beyond MS**: Plans to explore additional indications for Briumvi, including myasthenia gravis (MG) and neuromyelitis optica (NMO) [25][26] Competitive Landscape - **Market Positioning**: Briumvi is positioned as the lowest-priced branded MS treatment, enhancing its appeal in a competitive market [12][13] - **Sales Force Strategy**: Plans to increase the sales force by 10%-20% to target high-opportunity healthcare providers [14][34] R&D and Pipeline - **Azer-cel**: An allogeneic off-the-shelf CD19 CAR-T product in development for progressive MS, with data expected in 2026 [25][44] - **Long-term Opportunities**: Patents extending into the mid-2040s, with ongoing evaluations for new indications and potential drug launches [31] Key Takeaways - **Market Dynamics**: Briumvi's growth trajectory is strong, with significant market share gains and a robust pipeline for future growth [30][31] - **Operational Efficiency**: The company maintains low operating expenses relative to revenue, indicating potential for profitability acceleration [31][29] - **Patient Engagement**: Emphasis on patient awareness campaigns to drive market share, recognizing the importance of shared decision-making in MS treatment [15][16] Conclusion - TG Therapeutics is well-positioned for continued growth in the MS market with Briumvi, supported by strategic product development and a focus on patient and healthcare provider engagement. The company anticipates significant revenue growth and operational efficiency in the coming years, with a strong pipeline of future products and indications.

Core Viewpoint - TG Therapeutics, Inc. has released optimistic preliminary revenue estimates for Q4 2025 and a positive outlook for 2026, leading to a rise in stock price [1][3]. Revenue Estimates - The company expects Briumvi U.S. net product revenue to be approximately $182 million for Q4 2025 and $594 million for the full year of 2025, with total global revenue for 2025 estimated at around $616 million [2]. - For 2026, TG Therapeutics is targeting total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of about $825 to 850 million [2]. Market Performance - Briumvi has shown strong commercial performance in 2025, indicating a significant market share capture since its launch, which positions TG Therapeutics for long-term revenue growth and cash flow [3]. - Following the announcement, TG Therapeutics shares increased by 6.60%, reaching a price of $29.71 in extended trading [3].

TG Therapeutics FY Conference Summary Company Overview - **Company**: TG Therapeutics (NasdaqCM:TGTX) - **Product**: Briumvi, an anti-CD20 therapy for multiple sclerosis (MS) - **Market Presence**: Briumvi has been on the market for approximately 2.75 years, with a revenue target of $585 million for the current year [4][4] Financial Performance - **Revenue Target**: $585 million for FY 2025, with expectations for significant growth in FY 2026 [4][4] - **Future Guidance**: No specific guidance provided for next year, but anticipated to be a larger number than the current year [4][4] Market Dynamics - **CD20 Market Share**: Briumvi captures approximately 20% share among the CD20 class and about 10% share among all new MS starts [11][12] - **Patient Awareness**: Patient awareness was around 35% previously, with plans to double this over the next one to two years [19][19] Sales Strategy - **Sales Force Expansion**: TG Therapeutics plans to expand its sales force strategically, focusing on underperforming areas rather than a broad geographical expansion [25][27] - **Community vs. Hospital Practices**: The company is currently the second most prescribed in community settings and aims to become the number one in that category [26][26] Product Development - **Subcutaneous (Sub-Q) Program**: The Sub-Q program is progressing well, with enrollment expected to complete in the first half of next year and data anticipated by the end of next year [5][38] - **Formulation and Patents**: The new Sub-Q formulation is highly concentrated, with provisional patents filed that could extend protection until 2045 [42][42] Competitive Landscape - **Azer-cel and Cell Therapies**: The company is optimistic about the potential of cell therapies but acknowledges that current advancements are not yet transformative for patients with progressive forms of MS [50][51] - **Market Positioning**: TG Therapeutics aims to achieve parity coverage with competitors upon the launch of the Sub-Q formulation, expected in 2028 [45][45] Challenges and Considerations - **Gross-to-Net Spread**: The gross-to-net spread may be affected by 340B discounts, particularly in the hospital segment [33][33] - **Resource Management**: The company believes it can manage the expansion of its commercial and R&D efforts without significant strain, utilizing outsourcing for R&D as needed [59][60] Key Takeaways - TG Therapeutics is focused on increasing market share and patient awareness for Briumvi while strategically expanding its sales force - The company is optimistic about the future growth of its Sub-Q program and the potential of cell therapies - Resource management strategies are in place to handle potential growth in both commercial and R&D sectors without compromising execution quality [59][60]

Group 1 - The core viewpoint is that TG Therapeutics (TGTX) has experienced softer sales growth for its product Briumvi in recent quarters, leading to a hold rating due to potential for a TV campaign to boost sales in the near term [1] Group 2 - The article emphasizes the importance of trading around significant events such as trial results and NDA/BLA approvals in the biotech sector [1]

Group 1 - The core viewpoint indicates that TG Therapeutics (TGTX) experienced softer sales growth for Briumvi in recent quarters, leading to a hold rating due to potential for a TV campaign to boost near-term sales [1] Group 2 - The article emphasizes the importance of trading around significant events such as trial results and NDA/BLA approvals in the biotech sector [1]

Core Insights - Roche's fenebrutinib demonstrated "unprecedented" test results for multiple sclerosis, impacting TG Therapeutics negatively [1][2] - Roche's stock increased by over 3% to $43.33, while TG Therapeutics' stock fell more than 5% to $30.53, reaching a two-month low [2] - Fenebrutinib showed significantly fewer relapses compared to teriflunomide in relapsing multiple sclerosis patients [3] - In primary progressive MS, fenebrutinib slowed disability progression comparably to Roche's Ocrevus, the only approved treatment for this condition [4] Roche's Competitive Position - Roche's fenebrutinib uses a different mechanism than TG Therapeutics' Briumvi, targeting BTK, which is involved in immune response to inflammation [7] - Roche's stock performance improved, gapping above its 50-day moving average following the news [7] TG Therapeutics' Market Performance - Briumvi's sales grew by at least double-digit percentages year-over-year, with a notable 84% increase to $152.9 million in Q3 [6] - Despite the sales growth, Briumvi still lags behind Ocrevus in overall sales [6] - TG Therapeutics maintains a strong IBD Digital Composite Rating of 97, ranking in the top 3% of stocks for performance [8]

Core Insights - TG Therapeutics reported adjusted earnings of $2.43 per share and $161.7 million in sales for Q3, significantly exceeding analyst expectations of $0.22 earnings per share and $152.1 million in sales [1][2] - The earnings beat was primarily attributed to a one-time tax benefit of $365 million, which, if excluded, would have resulted in earnings closer to $0.15 per share [2] - The company raised its full-year sales guidance to $600 million, with $585 million expected from U.S. sales of its multiple sclerosis drug Briumvi [3] Financial Performance - Q3 adjusted earnings: $2.43 per share [1] - Q3 sales: $161.7 million [1] - Analyst expectations: $0.22 earnings per share and $152.1 million in sales [2] - Previous year Q3 earnings: $0.02 per share and $83.9 million in sales [2] - Revised full-year sales guidance: $600 million [3] Market Reaction - TG Therapeutics stock increased by 4.4% to $36.30 in premarket trading [3] - Shares are trading slightly above their 50-day moving average [3] Ratings and Upgrades - TG Therapeutics received an upgrade in its IBD SmartSelect Composite Rating from 94 to 97 [4][7] - The company is now part of an elite list of stocks with a composite rating above 95 [7]